Prevention of incipient diabetic cardiomyopathy by high-dose thiamine

Journal of Toxicological Sciences

Volumn 33, Issue 4, 2008, Pages 459-472

  Kohda, Yuka ^a   Shirakawa, Hisashi ^a   Yamane, Kazuhiko ^a   Otsuka, Kaoru ^a   Kono, Tatsuji ^a   Terasaki, Fumio ^a   Tanaka, Takao ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cardiac fibrosis; Diabetic cardiomyopathy; Hexosamine biosynthesis pathway; O GlcNAcylation; Thiamine

Indexed keywords

GLUCOSE; HEXOSAMINE; MESSENGER RNA; THIAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INJURY; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; RAT;

RATTUS;

EID: 55949130943     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.33.459     Document Type: Article

References (54)

1. Babaei-Jadidi, R., Karachalias, N., Ahmed, N., Battah, S. and Thornalley, P.J. (2003): Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes, 52, 2110-2120.
2. Beltramo, E., Berrone, E., Tarallo, S., Porta, M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Diabetol. Jun 26. Epub ahead of print, 2008
3. Bertoni, A.G., Tsai, A., Kasper, E.K. and Brancati, F.L. (2003): Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care, 26, 2791-2795.
4. Brownlee, M. (2001): Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-812.
5. Ceylan-Isik, A.F., Wu, S., Li, Q., Li, S.Y. and Ren, J. (2006): High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J. Appl. Physiol., 100, 150-156.
6. Comer, F.I. and Hart, G.W. (1999) O-GlcNAc and the control of gene expression. Biochim. Biophys. Acta, 1473, 161-171.
7. Daniel, C., Wiede, J., Krutzsch, H.C., Ribeiro, S.M., Roberts, D.D., Murphy-Ullrich, J.E. and Hugo, C. (2004): Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int., 65, 459-468.
8. Daniel, C., Schaub, K., Amann, K., Lawler, J. and Hugo, C. (2007): Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes, 56, 2982-2989.
9. Du, X.L., Edelstein, D., Rossetti, L., Fantus, I.G., Goldberg, H., Ziyadeh, F., Wu, J. and Brownlee, M. (2000): Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. PNAS, 97, 12222-12226.
10. Factor, S.M., Minase, T. and Sonnenblick, E.H. (1980): Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am. Heart J., 99, 446-458.
11. Ganguly, P.K., Pierce, G.N., Dhalla, K.S. and Dhalla, N.S. (1983): Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am. J. Physiol., 244, 528-535.
12. Giacomelli, F. and Wiener, J. (1979): Primary myocardial disease in the diabetic mouse. An ultrastructural study. Lab. Invest., 40, 460-473.
13. Greb, A. and Bitsch, R. (1998): Comparative bioavailability of various thiamine derivatives after oral administration. Int. J. Clin. Pharmacol. Ther., 36, 216-221.
14. Hammes, H.P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I. and Brownlee, M. (2003): Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med., 9, 294-299.
15. Hofmann, P.A., Menon, V. and Gannaway, K.F. (1995): Effects of diabetes on isometric tension as a function of [Ca2+] and pH in rat skinned cardiac myocytes. Am. J. Physiol. Heart. Circ. Physiol., 269, 1656-1663.
16. Hu, Y., Belke, D., Suarez, J., Swanson, E., Clark, R., Hoshijima, M. and Dillmann, W.H. (2005): Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ. Res., 96, 1006-1013.
17. Jermendy, G. (2006): Evaluating thiamine deficiency in patients with diabetes. Diab. Vasc. Dis. Res., 3, 120-121.
18. Kaiser, N., Sasson, S., Feener, E.P., Boukobza-Vardi, N., Higashi, S., Moller, D.E., Davidheiser, S., Przybylski, R.J. and King, G.L. (1993): Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes, 42, 80-89.
19. Kneass, Z.T. and Marchase, R.B. (2005): Protein O-GlcNAc modulates motiligy-associated signaling intermediates in neutrophils. J. Biol. Chem., 280, 14579-14585.
20. Koya, D., Jirousek, M.R., Lin, Y-W., Ishii, H., Kuboki, K. and King, G.L. (1997): Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest., 100, 115-126.
21. Kreppel, L.K., Blomberg, M.A. and Hart, G.W. (1997): Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem., 272, 9308-9315.
22. Lebiedzińska, A., Marszałł, M.L., Kuta, J. and Szefer, P. (2007): Reversed-phase high-performance liquid chromatography method with coulometric electrochemical and ultraviolet detection for the quantification of vitamins B(1) (thiamine), B(6) (pyridoxamine, pyridoxal and pyridoxine) and B(12) in animal and plant foods. J. Chromatogr. A., 1173, 71-80.
23. Lubas, W.A., Frank, D.W., Krause, M. and Hanover, J.A. (1997): O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem., 272, 9316-9324.
24. Marszall, M.L., Lebiedzinska, A., Czarnowski, W. and Szefer, P. (2005): High-performance liquid chromatography method for the simultaneous determination of thiamine hydrochloride, pyridoxine hydrochloride and cyanocobalamin in pharmaceutical formulations using coulometric electrochemical and ultraviolet detection. J. Chromatogr. A., 1094, 91-98.
25. Melhem, M.F., Craven, P.A. and Derubertis, F.R. (2001): Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. J. Am. Soc. Nephrol., 12, 124-133.
26. Mueckler, M. (1994): Facilitative glucose transporters. Eur. J. Biochem., 219, 713-725.
27. Obrenovich, M.E. and Monnier, V.M. (2003): Vitamin B1 Blocks Damage Caused by Hyperglycemia. Sci. Aging. Knowl. Environ., 2003, 6.
28. Patrini, C. and Lafarenza, U. (1996): Effects of insulin on thiamine intestinal transport in rat everted jejunal sacs. J. Physiol. (Lond.), 493, 100-101.
29. Piccini, J.P., Klein, L., Gheorghiade, M. and Bonow, R.O. (2004): New insights into diastolic heart failure: role of diabetes mellitus. Am. J. Med., 116 (Suppl. 1), 64-75.
30. Poirier, P., Bogaty, P., Garneau, C., Marois, L. and Dumesnil, J.G. (2001): Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care, 24, 5-10.
31. Ren, J. and Ceylan-Isik, A.F. (2004): Diabetic cardiomyopathy: do women differ from men? Endocrine, 25, 73-83.
32. Rindi, G. and Lafarenza, U. (2000): Thiamine intestinal transport and related issues: recent aspects. PSEBM., 224, 246-255.
33. Riva, E., Andreoni, G., Bianchi, R., Latini, R., Luvarà, G., Jeremic, G., Traquandi, C., Tuccinardi, L. (1998): Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol. Res., 37, 233-240.
34. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W. and Grishman, A. (1972): New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 30, 595-602.
35. Saito, N., Kimura, M., Kuchiba, A. and Itokawa, Y. (1987): Blood thiamine levels in outpatients with diabetes mellitus. J. Nutr. Sci. Vitaminol., 33, 421-430.
36. Seligmann, H., Halkin, H., Rauchfleisch, S., Kaufmann, N., Tal, R., Motro, M., Vered, Z. and Ezra, D. (1991): Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am. J. Med., 91, 151-155.
37. Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J.K. and Wilson, A.C. (1996): Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am. J. Cardiol., 77, 1017-1020.
38. Stepuro, I.I., Piletskaya, T.P., Stepuro, V.I. and Maskevich, S.A. (1997): Thiamine oxidative transformations catalyzed by copper ions and ascorbic acid. Biochemistry, 62, 1409-1414.
39. Tanaka, T., Sohmiya, K., Kono, T., Terasaki, F., Horie, R., Ohkaru, Y., Muramatsu, M., Takai, S., Miyazaki, M. and Kitaura, Y. (2007): Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol. Cell. Biochem., 299, 23-35.
40. Thornalley, P.J., Babaei-Jadidi, R., Al Ali, H., Rabbani, N., Antonysunil, A., Larkin, J., Ahmed, A., Rayman, G. and Bodmer, C.W. (2007): High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 50, 2164-2170.
41. 2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J., 18, 1967-1969.
42. Valerio, G., Franzese, A., Poggi, V., Patrini, C., Laforenza, U., Tenore, A. (1999): Lipophilic thiamine treatment in long-standing insulin-dependent diabetes mellitus. Acta. Diabetol., 36, 73-76.
43. Verrecchia, F., Rossert, J. and Mauviel, A. (2001): Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J. Invest. Dermatol., 116, 755-763.
44. Vosseller, K., Sakabe, K., Wells, L. and Hart, G.W. (2002): Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate post-translational modification. Curr. Opin. Chem. Biol., 6, 851-857.
45. Walgren, J.L., Vincent, T.S., Schey, K.L. and Buse, M.G. (2003): High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin. Am. J. Physiol. Endocrinol. Metab., 284, 424-434.
46. Wells, L. and Hart, G.W. (2003): O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett., 546, 154-158.
47. Wells, L., Whalen, S.A. and Hart, G.W. (2003): O-GlcNAc: a regulatory post-translational modification. Biochem. Biophys. Res. Commun., 302, 435-441.
48. Wells, L., Gao, Y., Mahoney, J.A., Vosseller, K., Chen, C., Rosen, A. and Hart, G.W. (2002): Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J. Biol. Chem., 277, 1755-1761
49. William, B.K., Marthana, H. and William, P.C. (1974): Role of diabetes in congestive heart failure: The Framingham Study. Am. J. Cardiol., 34, 29-34.
50. Williams, M.D. and Nadler, J.L. (2007): Inflammatory mechanisms of diabetic complications. Curr. Diab. Rep., 7, 242-248.
51. Wold, L.E., Ceylan-Isik, A.F. and Ren, J. (2005): Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta. Pharmacol. Sin., 26, 908-917.
52. Wu, S. and Ren, J. (2006): Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci. Lett., 394, 158-162.
53. Yang, X., Su, K., Roos, M.D., Chang, Q., Paterson, A.J. and Kudlow, J.E. (2001): O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. PNAS, 98, 6611-6616.
54. Yui, Y., Itokawa, Y. and Kawai, C. (1980): Furosemide induced thiamine deficiency. Cardiovasc. Res., 14, 537-540.